ArticleGut2022
PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.
Article in Gut, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06740149 (Efficacy and Safety of Allogeneic Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Patients With Acute-on-chronic Liver Failure), which is not on this map. Cited by 97 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Allogeneic Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Patients With Acute-on-chronic Liver Failure
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Guidelines for diagnosis and treatment of liver failure (2024 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Guideline
- Article
- ALPS-HCC Score: A Dynamic Liver Stiffness Measurement-Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Uncovering immune dysfunction in ACLF: Cellular mechanisms, molecular pathways, and therapeutic frontiers.Journal of hepatology · 2026Review
- [Analyzing research advances in single-cell sequencing technology for immunopathological mechanisms in acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management.Nature reviews. Gastroenterology & hepatology · 2026Review
- Comparative pathophysiological modeling: the advantage of "two-hit" over "one-hit" in acute liver failure studies.In vitro cellular & developmental biology. Animal · 2026Article
- Single-cell Sequencing Reveals Neutrophil Extracellular Traps in Association with Endotheliopathy and Immunothrombosis in Hepatitis B Virus-related Acute-on-chronic Liver Failure.Journal of clinical and translational hepatology · 2026Article
- MMP8/PPAR-γ regulation of macrophage-mediated inflammatory response in the pathogenesis of acute-on-chronic liver failure.Cell death & disease · 2026Article
- Mesenchymal stem cells-derived TGF-β1 promotes polarization of M2 macrophages in mice with acute-on-chronic liver failure via FOSL1/MERTK axis.Stem cell research & therapy · 2026Article
- Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression.Gut · 2026Article
- Risk factors for the development of cirrhosis within 1-year in non-cirrhotic patients with HBV- related acute-on-chronic liver failure.Frontiers in medicine · 2026Article
- Plasma gamma-glutamylglycine predicts the seroconversion of hepatitis B e antigen in patients with chronic hepatitis B.Frontiers in immunology · 2026Article
- Baseline CALLY index is associated with all-cause mortality in HBV-ACLF patients receiving ALSS therapy.Frontiers in medicine · 2026Article
- Article
- Mesenchymal Stem Cells Ameliorate Acute-on-Chronic Liver Failure Associated With Expansion of Immunoregulatory Hepatic NKp46Journal of immunology research · 2026Article
- Case Report: dynamic monocyte reprogramming during ALSS therapy in type B HBV-ACLF revealed by single-cell transcriptomics.Frontiers in immunology · 2026Article
- Cross-species hepatic transcriptomics identify conserved immune-metabolic reprogramming in acute-on-chronic liver failure progression.Frontiers in immunology · 2026Article
- A machine learning model for 90-day mortality prediction in hepatitis B virus-related acute-on-chronic liver failure: the pivotal role of CALLY index.Frontiers in medicine · 2026Article
- Association of nucleos(t)ide analogue treatment history with mortality in HBV-DNA-positive HBV-ACLF: a multicenter cohort study.Frontiers in immunology · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) pathophysiology remains unclear. This study aims to characterise the molecular basis of HBV-ACLF using transcriptomics.
methodsFour hundred subjects with HBV-ACLF, acute-on-chronic hepatic dysfunction (ACHD), liver cirrhosis (LC) or chronic hepatitis B (CHB) and normal controls (NC) from a prospective multicentre cohort were studied, and 65 subjects (ACLF, 20; ACHD, 10; LC, 10; CHB, 10; NC, 15) among them underwent mRNA sequencing using peripheral blood mononuclear cells (PBMCs).
resultsThe functional synergy analysis focusing on seven bioprocesses related to the PBMC response and the top 500 differentially expressed genes (DEGs) showed that viral processes were associated with all disease stages. Immune dysregulation, as the most prominent change and disorder triggered by HBV exacerbation, drove CHB or LC to ACHD and ACLF. Metabolic disruption was significant in ACHD and severe in ACLF. The analysis of 62 overlapping DEGs further linked the HBV-based immune-metabolism disorder to ACLF progression. The signatures of interferon-related, neutrophil-related and monocyte-related pathways related to the innate immune response were significantly upregulated. Signatures linked to the adaptive immune response were downregulated. Disruptions of lipid and fatty acid metabolism were observed during ACLF development. External validation of four DEGs underlying the aforementioned molecular mechanism in patients and experimental rats confirmed their specificity and potential as biomarkers for HBV-ACLF pathogenesis.
conclusionsThis study highlights immune-metabolism disorder triggered by HBV exacerbation as a potential mechanism of HBV-ACLF and may indicate a novel diagnostic and treatment target to reduce HBV-ACLF-related mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.